Position in MRK
as of Jun 30, 2026
· filed Jul 30, 2026
Position Value
$482,003
+$74,461 QoQ
Shares Held
3,751
+10.7% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.23%
of 13F equity value
Holder Rank
#2,726
of 3,769 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 16%
Shared 0%
None 84%
Common Shares in MRK Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Purkiss Capital Advisors LLC holds $8,883,228 across 7 Drug Manufacturers - General names. MRK ranks #5 (5.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
13,798 | $3,504,278 | |
| 2 | BMY |
Bristol Myers Squibb Co
|
36,627 | $2,110,447 | |
| 3 | LLY |
ELI LILLY & Co
|
939 | $1,126,264 | |
| 4 | ABBV |
AbbVie Inc.
|
4,355 | $1,095,892 | |
| 5 | MRK |
Merck & Co., Inc.
This page
|
3,751 | $482,003 | |
| 6 | AMGN |
Amgen Inc
|
898 | $325,183 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
1,893 | $239,161 |
All Filings in MRK
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $482,003 | 3,751 | Shares | Sole | 2026-07-30 | |
| 2026-03-31 | $407,542 | 3,388 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $355,778 | 3,380 | Shares | Sole | 2026-02-04 | |
| 2025-09-30 | $311,128 | 3,707 | Shares | Sole | 2025-10-31 | |
| 2025-06-30 | $366,194 | 4,626 | Shares | Sole | 2025-08-01 | |
| 2025-03-31 | $240,736 | 2,682 | Shares | Sole | 2025-05-07 | |
| 2024-12-31 | $238,155 | 2,394 | Shares | Sole | 2025-02-05 | |
| No filing history on record for this holder in this stock. | ||||||